title: Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease.
authors.affiliation: *Section of Pediatric Gastroenterology, Hepatology, Digestive Health Institute, Children's Hospital Colorado †Department of Pediatrics ‡Department of Pathology, National Jewish Health, Aurora, CO.
authors.forename: Glenn T
authors.initials: GT
authors.lastname: Furuta
authors.forename: Dan
authors.initials: D
authors.lastname: Atkins
authors.forename: Kelley E
authors.initials: KE
authors.lastname: Capocelli
authors.forename: Edwin F
authors.initials: EF
authors.lastname: de Zoeten
authors.forename: David
authors.initials: D
authors.lastname: Fleischer
authors.forename: Calies
authors.initials: C
authors.lastname: Menard-Katcher
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D004760:Enterocolitis / Q000188:drug therapy*; D004802:Eosinophilia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha